ArticleOncotarget2017
Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic potential of lipid profiling in cancer patients: a systematic review of mass spectrometry-based studies.Lipids in health and disease · 2024Pooled it
- The Contribution of Lipidomics in Ovarian Cancer Management: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Circulating Lipid Traits and Ovarian Cancer Risk: A Systematic Review and Meta-Analysis with Mendelian Randomization Integration.Metabolites · 2026Review
- Exploring translational relevance of baseline and longitudinal metabolic profiling in the blood of ovarian cancer patients.NPJ precision oncology · 2026Article
- Alterations in the Gut Microbiota and Metabolite Profiles of Lung Cancer Patients.Current microbiology · 2025Article
- Plasma proteomes and metabolism with genome-wide association data for causal effect identification in ovarian cancer.Discover oncology · 2025Article
- Blood metabolites reflect the effect of gut microbiota on differentiated thyroid cancer: a Mendelian randomization analysis.BMC cancer · 2025Article
- The strategic role of lipidomics in biomarker identification and diagnosis of gynecological diseases.Frontiers in endocrinology · 2025Review
- Development and validation of a nomogram to predict recurrence in epithelial ovarian cancer using complete blood count and lipid profiles.Frontiers in oncology · 2025Article
- Delineating lipidomic landscapes in human and mouse ovaries: Spatial signatures and chemically-induced alterations via MALDI mass spectrometry imaging: Spatial ovarian lipidomics.Environment international · 2024Article
- Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Lipidomics revealed alterations in glycerophospholipid metabolism in skin squamous cell carcinoma.Frontiers in molecular biosciences · 2024Article
- Ultrahigh Resolution Lipid Mass Spectrometry Imaging of High-Grade Serous Ovarian Cancer Mouse Models.bioRxiv : the preprint server for biology · 2023Article
- Tumor Microbial Communities and Thyroid Cancer Development-The Protective Role of Antioxidant Nutrients: Application Strategies and Future Directions.Antioxidants (Basel, Switzerland) · 2023Review
- The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus.Journal of translational medicine · 2023Review
- Ultrahigh resolution lipid mass spectrometry imaging of high-grade serous ovarian cancer mouse models.Frontiers in chemistry · 2023Article
- Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer.Scientific reports · 2022Article
- Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model.Cancers · 2022Article
- Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.Archives of gynecology and obstetrics · 2022Article
- Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most deadly gynecologic malignancy worldwide due to its high recurrence rate after surgery and chemotherapy. There is a critical need for discovery of novel biomarkers for EOC recurrence providing higher prediction power than that of the present ones. Lipids have been reported to associate with development and progression of cancer. In the current study, we aim to identify and validate the lipids which were relevant to the ovarian cancer recurrence based on plasma lipidomics performed by ultra-performance liquid chromatography coupled with mass spectrometry. In order to fulfill this objective, plasma from 70 EOC patients with follow up information was obtained. The results revealed that patients with and without recurrence could be clearly distinguished based on their lipid profiles. Thirty-one lipid metabolites were identified as potential biomarkers for EOC recurrence. The AUC value of these metabolite combinations for predicting EOC recurrence was 0.897. In terms of clinical applicability, LysoPG(20:5) arose as a potential EOC recurrence predictive biomarker to increase the predictive power of clinical predictors from AUC value 0.739 to 0.875. Additionally, we still found that individuals with early relapses (< 6 months) had a distinctive metabolomic pattern compared with late EOC and non-EOC recurrence subjects. Interestingly, decreased levels of triglycerides (TGs) were found to be a specific metabolic feature foreshadowing an early relapse. In conclusion, plasma lipidomics study could be used for predicting EOC recurrences, as well as early and late recurrent cases. The lipid biomarker research improves the predictive power of clinical predictors and the identified biomarkers are of great prognostic and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.